Filtered By:
Vaccination: Veterinary Vaccinations
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 437 results found since Jan 2013.
Animals are our overlooked allies in the fight against Covid | Melanie Challenger
It ’s important to recognise the vital role they’ve played in development of vaccines and treatmentsA few weeks ago, I received my first shot of a vaccine against Covid-19. As the newly vaccinated exited the clinic, there was a mix of relief and elation on people ’s faces. We exchanged little smiles of solidarity. If we could have burst into spontaneous applause, I’m sure we would have done.Recently, the lead scientist for the Oxford/AstraZeneca vaccine, Prof Sarah Gilbert,was honoured with the RSA Albert Medal. There are rumours that Gilbert ’s team, along with the pioneers of the mRNA vaccines, are up for a Nob...
Source: Guardian Unlimited Science - May 17, 2021 Category: Science Authors: Melanie Challenger Tags: Medical research Vaccines and immunisation Coronavirus Animals Science World news Source Type: news
Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Two New Studies Point to How AstraZeneca ’s COVID-19 Vaccine Is Linked to Blood Clots
In two papers published in the New England Journal of Medicine (NEJM), researchers in Europe provide the most detailed explanation yet for what is behind the clotting side effects reported among people getting vaccinated with the AstraZeneca COVID-19 shot.
In both papers, researchers found that people getting the vaccine had higher levels of antibodies directed against a cluster of immune-related cells that the body might form in response to the vaccine. These clusters include platelets, which help blood to clot when you get cut or injured, and the antibodies stick to the platelet-complex and form dangerous clots that can ...
Source: TIME: Health - April 9, 2021 Category: Consumer Health News Tags: Uncategorized COVID-19 Source Type: news
Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses
by John M. Powers, Nicole N. Haese, Michael Denton, Takeshi Ando, Craig Kreklywich, Kiley Bonin, Cassilyn E. Streblow, Nicholas Kreklywich, Patricia Smith, Rebecca Broeckel, Victor DeFilippis, Thomas E. Morrison, Mark T. Heise, Daniel N. Streblow
Mayaro virus (MAYV) is an alphavirus endemic to South and Central America associated with sporadic outbreaks in humans. MAYV infection causes severe joint and muscle pain that can persist for weeks to months. Currently, there are no approved vaccines or therapeutics to prevent MAYV infection or tr eat the debilitating musculoskeletal inflammatory disease. In the current study, a ...
Source: PLoS Neglected Tropical Diseases - April 1, 2021 Category: Tropical Medicine Authors: John M. Powers Source Type: research
Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® pl...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Fight Aging! Newsletter, January 25th 2021
In conclusion, our studies highlight the important role of the tyrosine degradation pathway and position TAT as a link between neuromediator production, dysfunctional mitochondria, and aging.
Source: Fight Aging! - January 24, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, January 11th 2021
This study demonstrates the potential of a natural (o-Vanillin) and a synthetic (RG-7112) senolytic compounds to remove senescent IVD cells, decrease SASP factors release, reduce the inflammatory environment and enhance the IVD matrix production. Removal of senescent cells, using senolytics drugs, could lead to improved therapeutic interventions and ultimately decrease pain and a provide a better quality of life of patients living with intervertebral disc degeneration and low back pain.
From Ying Ann Chiao of Oklahoma Medical Research Foundation: Mitochondrial dysfunction plays a central role in aging and cardiovasc...
Source: Fight Aging! - January 10, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with IMBRUVICA® remai...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
A Post-Pandemic Bucket List (and What To Do In the Meantime)
A version of this article appeared in It’s Not Just You, a new newsletter by Susanna Schrobsdorff, TIME Editor at Large. Subscribe here to have It’s Not Just You delivered to your inbox weekly.
🌞 Well hello! I’m so glad you’re here. This week we have some thoughts on life after COVID, a Taraji P. Henson TIME100 Talks interview about being vulnerable, gorgeous words from poet Ross Gay, plus a callout for your personal Person of the Year.
A POST-PANDEMIC BUCKET LIST
Oh, the things we’ll do when the vaccines are distributed and the pandemic is over! Don’t we all have a post-COVID...
Source: TIME: Health - December 6, 2020 Category: Consumer Health News Authors: Susanna Schrobsdorff Tags: Uncategorized Evergreen It's Not Just You Source Type: news
Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized to discont...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model
In this study, we have used the transiently immune-suppressed (IS) mouse model that MAb-5A3 was used to block IFN-I signaling in immune intact, wild-type mice at the time of CCHFV infection to evaluate the immune response and efficacy of the cell culture based and the mouse brain derived inactivated vaccines against CCHFV. Both vaccine preparations have provided complete protection but the cell culture based vaccine more effectively induced to CCFHV spesific antibodies and T cell responses. This is the first comparison of the cell culture based and the mouse brain derived vaccines for assessing the protective efficacy and ...
Source: PLoS Neglected Tropical Diseases - November 23, 2020 Category: Tropical Medicine Authors: Shaikh Terkis Islam Pavel Source Type: research
Fight Aging! Newsletter, November 23rd 2020
In conclusion, the study indicates that HBOT may induce significant senolytic effects that include significantly increasing telomere length and clearance of senescent cells in the aging populations.
Data on the Prevalence of Liver Fibrosis in Middle Age
https://www.fightaging.org/archives/2020/11/data-on-the-prevalence-of-liver-fibrosis-in-middle-age/
Fibrosis is a consequence of age-related disarray in tissue maintenance processes, leading to the deposition of scar-like collagen that disrupts tissue structure and function. It is an ultimately fatal issue for which there are only poor treatment options a...
Source: Fight Aging! - November 22, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Effect of the morphine/heroin vaccine on opioid and non-opioid drug-induced antinociception in mice.
This study found that the M-TT vaccine did not affect the antinociception induced by different doses of morphine or the ability of non-opioid and synthetic opioid drugs to decrease thermal pain. Moreover, the combination of vaccination and naloxone increased the time-course of morphine antagonism relative to either vaccination or naloxone alone. These results suggest that the antibody titers generated by the M-TT vaccine 1) are capable of reducing morphine-induced antinociception and 2) are selective enough not to alter antinociception induced by non-opioid or synthetic drugs. These characteristics support its potential as...
Source: European Journal of Pharmacology - November 7, 2020 Category: Drugs & Pharmacology Authors: Méndez SB, Matus-Ortega M, Miramontes RH, Salazar-Juárez A Tags: Eur J Pharmacol Source Type: research
Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutaneous for...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
